These findings prompt two considerations: (i) being increased in case of liver damage, Gas6 is a putative biomarker of CLD; (ii) being associated to development of liver fibrosis, targeting Gas6/TAM axis might be considered a potential therapeutic strategy in CLD. Here, GAS6 is linked to Hepatic fibrosis.